Cite

    Schaer, D., Li, Y., Castaneda, S., Inigo, I., Surguladze, D., Xu, X., Nugent, D., Murphy, M., Hall, G., Benhadji, K., Guba, S., Li, Y., Kalos, M., & Driscoll, K. (2015). targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Journal for immunotherapy of cancer, 3(2), 1–2. http://access.bl.uk/ark:/81055/vdc_100080441580.0x0003ab